- Home
- AEON vs BIAF Comparison
AEON vs BIAF Comparison
Compare AEON & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- BIAF
- Stock Information
- Founded
- AEON N/A
- BIAF 2014
- Country
- AEON United States
- BIAF United States
- Employees
- AEON N/A
- BIAF N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AEON Health Care
- BIAF Health Care
- Exchange
- AEON Nasdaq
- BIAF Nasdaq
- Market Cap
- AEON 8.0M
- BIAF 7.1M
- IPO Year
- AEON N/A
- BIAF 2022
- Fundamental
- Price
- AEON $0.73
- BIAF $0.24
- Analyst Decision
- AEON Strong Buy
- BIAF Hold
- Analyst Count
- AEON 1
- BIAF 1
- Target Price
- AEON $360.00
- BIAF N/A
- AVG Volume (30 Days)
- AEON 85.9K
- BIAF 479.5K
- Earning Date
- AEON 08-12-2025
- BIAF 08-14-2025
- Dividend Yield
- AEON N/A
- BIAF N/A
- EPS Growth
- AEON N/A
- BIAF N/A
- EPS
- AEON N/A
- BIAF N/A
- Revenue
- AEON N/A
- BIAF $7,681,059.00
- Revenue This Year
- AEON N/A
- BIAF N/A
- Revenue Next Year
- AEON N/A
- BIAF $20.00
- P/E Ratio
- AEON N/A
- BIAF N/A
- Revenue Growth
- AEON N/A
- BIAF 4.99
- 52 Week Low
- AEON $0.38
- BIAF $0.16
- 52 Week High
- AEON $115.57
- BIAF $2.26
- Technical
- Relative Strength Index (RSI)
- AEON 48.08
- BIAF 39.52
- Support Level
- AEON $0.72
- BIAF $0.24
- Resistance Level
- AEON $0.80
- BIAF $0.26
- Average True Range (ATR)
- AEON 0.06
- BIAF 0.02
- MACD
- AEON 0.00
- BIAF -0.00
- Stochastic Oscillator
- AEON 59.94
- BIAF 26.48
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.